Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Gender differences in physical morbidity in opioid agonist treatment patients: population-based cohort studies from the Czech Republic and Norway

G. Rolová, D. Eide, R. Gabrhelík, I. Odsbu, T. Clausen, S. Skurtveit

. 2023 ; 18 (1) : 47. [pub] 20230728

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016809

BACKGROUND: Physical diseases represent a significant burden for opioid agonist treatment (OAT) patients. This study described physical morbidity in two national cohorts of OAT patients focusing on gender differences. METHODS: This population-based cohort study linking multiple health registers investigated physical diseases (ICD-10) in patients receiving OAT in the Czech Republic (N = 4,280) and Norway (N = 11,389) during 2010-2019. Gender-stratified analysis was performed. RESULTS: Overall, we found a large burden of physical morbidity across gender groups in OAT patients. In the Czech Republic and Norway, women in OAT had a significantly higher prevalence of physical diseases across most diagnostic chapters, notably genitourinary diseases and neoplasms. Injuries/external causes and infectious/parasitic diseases were among the most common diseases in both women and men. Viral hepatitis accounted for over half of infectious morbidity in women and men in both cohorts. CONCLUSIONS: Our findings support the need for early screening, detection, and treatment of diseases and conditions across organ systems and the integration of health promotion activities to reduce physical morbidity in OAT patients. The gender differences underline the need for a tailored approach to address specific medical conditions.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016809
003      
CZ-PrNML
005      
20231026105527.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13011-023-00557-8 $2 doi
035    __
$a (PubMed)37507709
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rolová, Gabriela $u First Faculty of Medicine, Department of Addictology, Charles University, Prague, Czech Republic. gabriela.rolova@lf1.cuni.cz $u Department of Addictology, General University Hospital, Prague, Czech Republic. gabriela.rolova@lf1.cuni.cz $1 https://orcid.org/0000000272387449
245    10
$a Gender differences in physical morbidity in opioid agonist treatment patients: population-based cohort studies from the Czech Republic and Norway / $c G. Rolová, D. Eide, R. Gabrhelík, I. Odsbu, T. Clausen, S. Skurtveit
520    9_
$a BACKGROUND: Physical diseases represent a significant burden for opioid agonist treatment (OAT) patients. This study described physical morbidity in two national cohorts of OAT patients focusing on gender differences. METHODS: This population-based cohort study linking multiple health registers investigated physical diseases (ICD-10) in patients receiving OAT in the Czech Republic (N = 4,280) and Norway (N = 11,389) during 2010-2019. Gender-stratified analysis was performed. RESULTS: Overall, we found a large burden of physical morbidity across gender groups in OAT patients. In the Czech Republic and Norway, women in OAT had a significantly higher prevalence of physical diseases across most diagnostic chapters, notably genitourinary diseases and neoplasms. Injuries/external causes and infectious/parasitic diseases were among the most common diseases in both women and men. Viral hepatitis accounted for over half of infectious morbidity in women and men in both cohorts. CONCLUSIONS: Our findings support the need for early screening, detection, and treatment of diseases and conditions across organ systems and the integration of health promotion activities to reduce physical morbidity in OAT patients. The gender differences underline the need for a tailored approach to address specific medical conditions.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a opioidní analgetika $x terapeutické užití $7 D000701
650    _2
$a sexuální faktory $7 D012737
650    _2
$a kohortové studie $7 D015331
650    _2
$a opiátová substituční terapie $7 D058850
650    _2
$a prevalence $7 D015995
650    12
$a poruchy spojené s užíváním opiátů $x farmakoterapie $x epidemiologie $7 D009293
651    _2
$a Česká republika $x epidemiologie $7 D018153
651    _2
$a Norsko $7 D009664
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Eide, Desiree $u University of Oslo, Norwegian Centre for Addiction Research, Oslo, Norway $1 https://orcid.org/0000000241159099
700    1_
$a Gabrhelík, Roman $u First Faculty of Medicine, Department of Addictology, Charles University, Prague, Czech Republic $u Department of Addictology, General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000276723753 $7 js20060217003
700    1_
$a Odsbu, Ingvild $u First Faculty of Medicine, Department of Addictology, Charles University, Prague, Czech Republic $u Norwegian Institute of Public Health, Oslo, Norway $1 https://orcid.org/0000000253378619
700    1_
$a Clausen, Thomas $u University of Oslo, Norwegian Centre for Addiction Research, Oslo, Norway $1 https://orcid.org/0000000224214201
700    1_
$a Skurtveit, Svetlana $u University of Oslo, Norwegian Centre for Addiction Research, Oslo, Norway $u Norwegian Institute of Public Health, Oslo, Norway $1 https://orcid.org/0000000175259701
773    0_
$w MED00207786 $t Substance abuse treatment, prevention, and policy $x 1747-597X $g Roč. 18, č. 1 (2023), s. 47
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37507709 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105522 $b ABA008
999    __
$a ok $b bmc $g 2000385 $s 1203171
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c 1 $d 47 $e 20230728 $i 1747-597X $m Substance abuse treatment, prevention, and policy $n Subst Abuse Treat Prev Policy $x MED00207786
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace